AI assistant
Sending…
4D Molecular Therapeutics, Inc. — Director's Dealing 2021
Apr 14, 2021
33060_dirs_2021-04-14_1b439cc1-be6d-49f3-b7a7-e26ed2deeab8.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: 4D Molecular Therapeutics Inc. (FDMT)
CIK: 0001650648
Period of Report: 2021-04-12
Reporting Person: Moretti August J (Chief Financial Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2021-04-12 | Common Stock | M | 1000 | $9.41 | Acquired | 2000 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2021-04-12 | Stock Option (Right to Buy) | $9.41 | M | 1000 | Disposed | 2029-03-19 | Common Stock (1000) | Direct |
Footnotes
F1: The stock option is partially vested and will vest with respect to the remaining shares in equal monthly installments until fully vested on January 7, 2023.
More from 4D Molecular Therapeutics, Inc.
Regulatory Filings
2026
May 7
Major Shareholding Notification
2026
Mar 26
Director's Dealing
2026
Mar 24
Regulatory Filings
2026
Mar 18
Major Shareholding Notification
2026
Feb 17
Major Shareholding Notification
2026
Feb 17
Major Shareholding Notification
2026
Feb 17
Major Shareholding Notification
2026
Feb 17
Regulatory Filings
2026
Jan 26
Director's Dealing
2026
Jan 8